SCHEMBL6947583

SCHEMBL6947583

CCCC[C@H](CCC)C(N)=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.75
CA1 P00915 4/20 0.75
MAPK1 P28482 1/20 0.52
SLC1A2 P43004 3/20 0.48
SLC1A1 P43005 3/20 0.48
SLC1A3 P43003 2/20 0.48
CHRM1 P11229 1/20 0.48
AKR1A1 P14550 1/20 0.48
CHRM3 P20309 1/20 0.48
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
ADRA1A P35348 1/20 0.48
HRH1 P35367 1/20 0.48
DRD3 P35462 1/20 0.48
SLC6A3 Q01959 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CYP3A4 P08684 2/20 0.46
TSHR P16473 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3349103 1.00 CA2 (0.75) CA2CA1MAPK1SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL28806599 0.98 CA2 (0.72) CA2CA1MAPK1SLC1A2SLC1A1
SCHEMBL2369450 0.95 CA2 (0.82) CA2CA1MAPK1SLC1A2SLC1A1
SCHEMBL3856960 0.93 CA2 (0.65) CA2CA1MAPK1SLC1A2SLC1A1
SCHEMBL4151185 0.93 CA2 (0.65) CA2CA1MAPK1SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL3023637 0.93 CA2 (0.78) CA2CA1MAPK1SLC1A2SLC1A1
SCHEMBL7638666 0.93 CA2 (0.78) CA2CA1MAPK1SLC1A2SLC1A1
SCHEMBL1672036 0.91 CA2 (0.63) CA2CA1SLC1A2SLC1A1CHRM1
SCHEMBL7209672 0.91 CA2 (0.63) CA2CA1SLC1A2SLC1A1CHRM1
SCHEMBL3861238 0.91 CA2 (0.63) CA2CA1SLC1A2SLC1A1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production THOMPSON LORIN A (US) 2003-12-18 US disclosed
EP-1268454-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2003-01-02 EP disclosed
WO-2001074796-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A CA2 2594/4885CA1 1679/4885MAPK1 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.